Tjalf Z.
- Country
- Germany
- Department
- Zentrum für klinische Neurowissenschaften an der Neurologischen Universitätsklinik Dresden
Research Overview
- Investigation of RO7121932 Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics in Multiple Sclerosis Patients
- Pharmacokinetic, Safety, Tolerability, Immunogenicity and Pharmacodynamic Evaluation of Subcutaneous Ocrelizumab in Pediatric Relapsing‑Remitting Multiple Sclerosis
- Long-term Safety and Efficacy Evaluation of Ocrelizumab in Multiple Sclerosis Patients from Phase III Studies
Data & Insights
Has run more than one trial at 260 of 435 partner sites.
Specializations
Multiple Sclerosis Treatment Innovation
This investigator specializes in evaluating novel therapeutic approaches for multiple sclerosis, with particular emphasis on both relapsing and progressive forms of the disease.
- Relapsing Multiple Sclerosis (RMS) Therapies
- Progressive Multiple Sclerosis Management
- Pediatric MS Treatment Strategies
A key focus includes assessment of targeted immunological therapies and comparative treatment efficacy.
Advanced Therapeutic Modalities
The investigator conducts research into innovative treatment approaches including CAR T-cell therapy and Bruton's Tyrosine Kinase inhibitors for neurological conditions.
- Immunomodulatory Treatments
- Cell-based Therapies
- Novel Molecular Targets
Expertise extends to evaluating long-term safety and effectiveness of experimental therapeutic agents.
Neurological Disease Management
Research activities encompass comprehensive evaluation of disease progression and therapeutic responses in neurological conditions.
- Brain Inflammation Assessment
- Disability Progression Monitoring
- Treatment Safety Protocols
Studies include advanced imaging techniques and clinical outcome measures in neurological diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.